Answers are grounded in this paper and cite their sources.
In 1982, when the Orphan Drug Act was passed as an amendment to the Federal Food, Drug, and Cosmetic Act,1 few suspected the extent to which this law would alleviate the plight of patients with rare diseases. The law defines an orphan drug as one with efficacy against a disease affecting fewer than 200,000 people in the United States or one that scientists and economists at the Food and Drug Administration (FDA) determine will not be profitable for seven years after FDA approval.2 In the 24 years since this law was passed, 282 such drugs and biologic products, providing treatment . . .
No takes yet. Share an insight, caveat, or question.
Marlene E. Haffner (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: